A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

Also called NCT01280695

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 129 participants (enrolled count) (from the registry)
Sponsor
Metabolic Solutions Development Company (from the registry)
Registry
  • NCT NCT01280695
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01280695. Randomized; quadruple masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2011-06 (actual). Results posted on 2013-12-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
MSDC-0602 100 mg
Intervention (Drug)
MSDC-0602 250 mg
Intervention (Drug)
MSDC-0602 250 mg
Intervention (Drug)
Pioglitazone
Lead sponsor
Metabolic Solutions Development Company (class: industry)

Record details

Record id
cardio:ct-nct01280695
Content hash
48eb380f12bcd00427038d38309b11266426cb43055e6f90f1c51ee177b036f7